A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed by Ofatumumab-Alemtuzumab in 17p Deletion CLL
Latest Information Update: 31 Aug 2023
At a glance
- Drugs Ofatumumab (Primary) ; Alemtuzumab; Methylprednisolone
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 06 Jun 2019 Status changed from active, no longer recruiting to discontinued.
- 25 May 2017 Status changed from recruiting to active, no longer recruiting.
- 06 May 2016 Status changed from active, no longer recruiting to recruiting.